Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin Prophylaxis in Acute Leukemia (PROFIL-C)
NCT00501098Phase 2Completed
- Sponsor
- Northern Italy Leukemia Group
- Start
- Jan 2007
- Primary completion
- Dec 2008
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of caspofungin in Invasive Pulmonary Aspergillosis (IPA), sponsored by Northern Italy Leukemia Group. Primary endpoint: Occurrence of probable/proven invasive aspergillosis. Started Jan 2007; status: completed.
02
Drugs
caspofungin
03
Conditions
Invasive Pulmonary Aspergillosis (IPA)
Beyond the preview
Go deeper on NCT00501098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00501098.